1-5 of 5
Anna F. Farago
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes

Catherine B. Meador, Subba R. Digumarthy, Beow Y. Yeap, Yin P. Hung, Mari Mino-Kenudson, Anna F. Farago, Rebecca S. Heist, J. Paul Marcoux, Deepa Rangachari, David A. Barbie, Zofia Piotrowska
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 25–34.
https://doi.org/10.1158/1078-0432.CCR-24-2350
Published: 06 January 2025
View article titled, Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes
Open the PDF for Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes in another window
Includes: Supplementary data
Journal Articles

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

Harshabad Singh, Yvonne Y. Li, Liam F. Spurr, Atul B. Shinagare, Ritika Abhyankar, Emma Reilly, Lauren K. Brais, Anwesha Nag, Matthew D. Ducar, Aaron R. Thorner, Geoffrey I. Shapiro, Rachel B. Keller, Cheta Siletti, Jeffrey W. Clark, Anna F. Farago, Jessica J. Lin, George D. Demetri, Rahul Gujrathi, Matthew H. Kulke, Laura E. MacConaill, Azra H. Ligon, Ewa Sicinska, Matthew L. Meyerson, Jeffrey A. Meyerhardt, Andrew D. Cherniack, Brian M. Wolpin, Kimmie Ng, Marios Giannakis, Jason L. Hornick, James M. Cleary
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1695–1705.
https://doi.org/10.1158/1078-0432.CCR-20-4073
Published: 15 March 2021
View article titled, Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Open the PDF for Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Davila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (23): 6958–6966.
https://doi.org/10.1158/1078-0432.CCR-19-1133
Published: 02 December 2019
View article titled, Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Open the PDF for Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study in another window
Includes: Supplementary data
Journal Articles

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (22): 6662–6670.
https://doi.org/10.1158/1078-0432.CCR-19-1436
Published: 15 November 2019
View article titled, Treatment with Next-Generation ALK Inhibitors Fuels Plasma <em>ALK</em> Mutation Diversity
Open the PDF for Treatment with Next-Generation ALK Inhibitors Fuels Plasma <em>ALK</em> Mutation Diversity in another window
Includes: Supplementary data
Journal Articles

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba Digumarthy, Teresa Moran, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino-Kenudson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4585–4593.
https://doi.org/10.1158/1078-0432.CCR-15-3101
Published: 15 September 2016
View article titled, <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Open the PDF for <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis in another window
Includes: Supplementary data